Thursday, November 26

Junshi and Impact to Establish Joint Venture for Senaparib (IMP4297) in China

 Junshi and Impact to Establish Joint Venture for Senaparib (IMP4297) in China Junshi and Impact to Establish Joint Venture for Senaparib (IMP4297) in China

Junshi and Impact to Establish Joint Venture for Senaparib (IMP4297) in China

Shots:

  • The two companies will co-develop and conduct clinical trials for senaparib across multiple cancer indications in China. Junshi to invest $43.4M in cash, representing 50% of the JV while Impact will supply senaparib in Mainland China, Hong Kong, and Macau representing the other 50%
  • The JV will focus on the research, development & commercialization of the therapy in the territory. Both the companies will leverage the team’s strength to expedite the clinical development of IMP4297 and explore additional indications with the therapy
  • Senaparib is a PARP inhibitor, currently being evaluated in multiple P-I & II studies in multiple settings. The drug has been tested in 100+ patients with advanced solid tumors in multiple clinical trials in China and Australia

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Modern Medicines


Post Views:
5

Leave a Reply

Your email address will not be published. Required fields are marked *